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Abstract As a continuation of “Postmortem Chemistry
Update Part I,” Part II deals with molecules linked to liver
and cardiac functions, alcohol intake and alcohol misuse,
myocardial ischemia, inflammation, sepsis, anaphylaxis,
and hormonal disturbances. A very important array of new
material concerning these situations had appeared in the
forensic literature over the last two decades. Some
molecules, such as procalcitonin and C-reactive protein,
are currently researched in cases of suspected sepsis and
inflammation, whereas many other analytes are not inte-
grated into routine casework. As in part I, a literature
review concerning a large panel of molecules of forensic
interest is presented, as well as the results of our own
observations, where possible.
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Introduction
As a continuation of “Postmortem Chemistry Update Part
I,” Part II deals with a large panel of molecules implicated
in many forensic situations. As in part one, our attention
has been placed on molecules which could provide
information in determining the cause of death and not
those concerning the time of death. Some of the molecules
investigated have already been explored by Coe, though
many others are more recent in forensic practice. Numerous
publications have hence appeared over the last two decades.
A literature review concerning the postmortem evaluation
of liver and cardiac functions, markers of alcohol misuse
and alcohol intake, myocardial ischemia, sepsis, inflamma-
tion, infection and anaphylaxis as well as some hormones is
herein presented, along with results of our experiences,
where possible.
Liver
Liver function
The metabolic functions of the liver include the processing
of amino acids, carbohydrates, lipids, and vitamins; serum
protein synthesis; detoxification; and excretion into bile of
endogenous waste products and xenobiotics [1]. Measure-
ments of total cholesterol and triglycerides in postmortem
serum and other fluids have been performed in the past and
have been associated with the presence of coronary heart
disease and sudden cardiac death [2]. Coe [3] reported that
total serum cholesterol stays in the normal range after death
and postmortem levels correlate closely with antemortem
values, in both high and low concentrations. Särkioja et al.
[4] investigated the stability of total cholesterol, triglycer-
ides, and apolipoproteins B and A-I in postmortem serum
from peripheral blood and found that unpredictable fluctua-
tions occurred in the postmortem values of lipids and
lipoproteins already in the first 24 h after death, rendering
the estimation of antemortem lipid levels from postmortem
samples difficult. Uemura et al. [5] investigated 11
clinically available biochemical markers (including total
cholesterol and triglycerides) in postmortem serum from
three sampling sites (left cardiac blood, right cardiac blood,
and femoral vein blood) in 164 consecutive autopsy cases.
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The mean triglyceride levels were comparable among the
sampling sites though higher than in living subjects and
easily affected by ingestion or starvation, suggesting that
this parameter was not useful as a postmortem marker. Total
cholesterol levels showed a tendency to decrease time
dependently and showed differences according to sampling
sites. Among them, the highest values were observed in
postmortem serum from left cardiac blood, which was
therefore recommended as the sample of choice. Total
cholesterol levels were reliable as postmortem markers
when carefully interpreted in an appropriate limit range.
Bilirubin levels slightly increase after death though, in
individuals with jaundice, the postmortem increase is
relatively small and does not interfere with determining
the degree of antemortem jaundice [2, 3]. Uemura et al. [5]
investigated total bilirubin in postmortem serum from three
sampling sites (left cardiac blood, right cardiac blood, and
femoral vein blood) in 164 consecutive autopsy cases and
found that this parameter tended to show a time-dependent
increase, although not significant, and could provide
reliable data useful in a clinical context. Again, postmortem
serum from femoral vein blood was proposed as the sample
of choice. Measurements of total proteins in postmortem
serum provide valid data, exploitable in the clinical context
[2, 3]. Uemura et al. [5] investigated total proteins in
postmortem serum from three sampling sites (left cardiac
blood, right cardiac blood, and femoral vein blood) in 164
consecutive autopsy cases and found that postmortem
protein levels could provide reliable data. Postmortem
serum from femoral vein blood was proposed as the sample
of choice.
Postmortem serum transaminase levels increased rapidly
and unpredictably [2, 3]. γ-Glutamyl transpeptidase (γ-GT)
in postmortem serum was designated as stable by Piette and
De Schrijver [6] and unpredictable by Sadler et al. [7].
Uemura et al. [5] investigated γ-GT levels in 164 autopsy
cases at various sampling sites and found that the
concentrations tended to be too dissimilar from those in
living subjects to use this parameter as a reliable postmortem
marker.
Markers of alcohol misuse and alcohol intake
Carbohydrate-deficient transferrin
Serum transferrin (Tf) is an iron-transporting glycoprotein
synthesized mainly by hepatocytes. It is composed of 679
amino acids with two potential glycosylation sites that
usually bind two biantennary and/or triantennary carbohy-
drate chains of variable compositions, containing four
different carbohydrates (N-acetylglucosamine, mannose,
galactose, and sialic acid terminals). Sialic acid is the only
charged moiety in these chains, and, when present, gives a
negative charge to the Tf molecule. Tf occurs in at least seven
isoforms: hexasialo, pentasialo, tetrasialo, trisialo, disialo,
monosialo, and asialo transferrin. In healthy organisms, the
tetrasialo isoform accounts for about 80% of the total
circulating Tf. Elevated alcohol intake decreases the hepatic
glycosylation of Tf, and consequently increases the amounts
of Tf isoforms deficient in terminal oligosaccharides (mainly
asialo and disialo Tf), referred to as carbohydrate-deficient
transferrin (CDT). Alcohol intake of >50–80 g/day for
1–2 weeks is believed to lead to an increase in serum
CDT, which has a half-life of about 15 days [8–11]. A
review of the literature concerning the determination of CDT
in postmortem samples has been recently reported by Rainio
et al. [10] who examined the studies performed on this topic
by several authors on different biological substrates between
1996 and 2008.
Simonnet et al. [12] investigated the influence of several
factors (haemolysis, sampling site, storage, and repeated
cycles of freezing and thawing) on CDT concentration in
serum samples obtained from living individuals and
autopsy cases (postmortem serum samples). Their results
showed that the site of sampling had no influence on the
CDT concentrations and that the molecule remained stable
even under stringent experimental storage conditions,
whereas haemolysis and repeated freezing and thawing
were responsible for decreased CDT levels.
Malcolm et al. [13] evaluated the stability of CDT in 25
forensic autopsy cases and did not find any correlation
between postmortem serum CDT levels (postmortem serum
from heart blood or other main sources as the aorta) and the
time elapsed from death to the sample collection, suggesting
that CDT levels were stable for at least 36 h after death.
Osuna et al. [14] and Berkowicz et al. [15, 16]
investigated the usefulness of the postmortem determina-
tion of CDT in vitreous. Osuna et al. [14] performed a study
on vitreous samples collected from 66 autopsy cases (38
alcohol abusers and 28 control cases). Berkowicz et al.
performed a study on vitreous samples collected from 28
autopsy cases (21 alcohol abusers and seven control cases).
Both studies showed that the determination of vitreous
CDT could be useful in detecting heavy alcohol consump-
tion. The results of the study of Berkowicz et al. [15, 16]
also suggested the possibility that time-dependent changes
in vitreous Tf could interfere with vitreous CDT values.
Rainio et al. [17] compared the concentrations of CDT in
postmortem serum from various sampling sites (left and
right femoral vein and inferior vena cava) and concluded
that CDT was not subject to substantial postmortem
redistribution. Results of this study also revealed that
CDT concentrations were mostly unchanged after several
days of cold body storage, implying that the postmortem
time did not influence analytical results to any significant
degree.
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Ethyl glucuronide and ethyl sulphate
Ethyl glucuronide (EtG) is a non-volatile, water-soluble,
stable-upon-storage, direct metabolite of ethanol which can
be detected in body fluids and tissues (as well as in
postmortem samples) for an extended time period after the
complete elimination of ethanol from the body. EtG has been
detected up to 8 h in blood and up to 80 h in urine after ethanol
intake. Moreover, the determination of EtG in hair offers a
comparatively long period of detection up to several months.
EtG is considered a marker of ethanol intake rather than
misuse. Several studies have been performed in the last
decade on numerous postmortem substrates, including hair,
blood, liver, skeletal muscle, adipose tissue, urine, bile, and rib
bone marrow [10, 18–41].
Yegles et al. [25] determined the concentrations of EtG
and fatty acid ethyl esters (another product of non-oxidative
ethanol metabolism) in the hair specimens of several
categories of living subjects, including ten alcoholics in
withdrawal treatment and 11 samples from autopsies. They
compared both markers with self-reported data pertaining to
alcohol consumption. Their results showed different distribu-
tions in the hair for both markers, leading to the conclusion
that a time-resolved drinking history of subjects could not be
ascertained by the corresponding segmental concentrations of
EtG and fatty acid ethyl esters.
Schloegl et al. [27] examined the stability of EtG in
several substrates including urine from volunteers and
postmortem specimens. The study was carried out on urine
samples of nine volunteers who had consumed different
amount of alcohol during the previous evening, stored up to
5 weeks at room temperature and at 4°C. Postmortem
blood, liver, and skeletal muscle samples from seven
autopsies, with positive and negative blood alcohol con-
centrations, stored after sampling at room temperature for
up to 4 weeks were also included in the study. Ethanol was
added to a part of the blood and liver samples of corpses
with negative blood alcohol concentrations. In urine
samples, EtG was a stable marker when stored at 4°C for
5 weeks, whereas in samples stored at higher temperatures
larger variations of EtG concentrations were detected
during 5 weeks of storage. In EtG-positive tissue material,
a slow decrease in EtG concentration over 4 weeks of
storage at room temperature was observed. Lastly, all EtG-
negative tissue samples remained negative for up to 4 weeks
of storage at room temperature, suggesting that the presence
of EtG in body liquid or tissues prove alcohol consumption
prior to death. In a subsequent study performed on several
substrates (rib bone marrow, liver and skeletal muscle
samples, fat tissue, urine, blood, and bile) from 12
autopsies, they observed that rib bone marrow could be
helpful in detecting EtG concentrations in cases where
other material was not available [28].
Høiseth et al. [31, 32] studied the pertinence of EtG
measurements in postmortem blood samples. They found
that EtG had a high specificity for alcohol ingestion,
indicating that no EtG was produced endogenously, even
when ethanol was formed postmortem. The authors also
emphasized that the absence of EtG in postmortem blood
samples, especially in heavily putrefied cases, must be
interpreted with caution due to EtG degradation. This
would further suggest the importance of analysing addi-
tional media to determine whether or not ethanol was
ingested. However, Helander et al. [41] reported postcol-
lection synthesis of EtG in urine in the presence of ethanol
and Escherichia coli.
Ethyl sulphate (EtS), a direct ethanol metabolite formed
by sulphate conjugation, has been recently indicated as a
biomarker for recent alcohol consumption, with excretion
characteristics similar to those of EtG. Moreover, since EtS
and EtG are formed via different pathways, either may be
used to identify recent ethanol intake [38, 42–46].
Baranowski et al. [43] performed a study with in vitro
experiments, in order to ascertain EtG and EtS degradation
from bacterial colonies isolated from autopsy material (13
cases). Their results showed that EtG was completely
degraded by bacteria with β-glucuronidase activity in a range
of 3–4 days, whereas EtS was not affected by degradation
within 11 days of incubation. However, Halter et al. [44]
showed the possibility of EtS bacterial degradation in
extreme conditions, leading to the conclusion that EtS
degradation should be taken into account when alcohol
intake some hours prior to death needs to be excluded,
especially in putrefied corpses.
Thierauf et al. [46] collected samples of urine, femoral
vein blood, and vitreous from 26 deceased cases with
assumed ethanol consumption prior to death, in order to
determine EtG, EtS, and ethanol concentrations and to
compare the vitreous levels with blood and urine levels. No
evidence of a concentration or distribution pattern of
ethanol, EtG, and EtS was observed and a constant
relationship among the three analytes could not be
established. However, this study showed that vitreous could
be used as a substrate for the detection and determination of
ethanol, EtG, and EtS.
Cardiac function
ANP, BNP, and N-terminal propeptides
Atrial natriuretic peptide (ANP) and brain natriuretic
peptide (BNP) are small peptides consisting of 28 and 32
amino acid residues, synthesized and secreted from the
atrial and ventricular myocardium, respectively. Atrial and
ventricular cardiomyocytes produce proANP and proBNP,
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which are cleaved into the biologically active ANP and
BNP and their amino-terminal counterparts (NT-proANP
and NT-proBNP). Increased cardiac pressure or volume as
well as neurohumoral factors can trigger the synthesis and
release of peptides derived from proANP and proBNP.
Circulating concentrations of ANP and NT-proANP pri-
marily reflect increased preload, whereas BNP and NT-
proBNP concentrations primarily reflect increased heart
afterload [47–59].
Zhu et al. [59] investigated ANP and BNP levels in the
pericardial fluid of 263 medico-legal autopsy cases and
found that both markers showed negative correlations with
cardiac troponin T levels in pericardial fluid, suggesting
that their production by cardiac tissue was reduced depend-
ing on the severity of myocardial damage. A significant
elevation in pericardial ANP levels, in contrast to mildly
elevated BNP levels, was observed in drowning cases.
According to the authors, this result depended on multiple
factors, including cardiac dysfunction due to electrolyte
disturbance, acute atrial overload involving increased wall
tension and pulmonary hypertension caused by water
aspiration, or stretched atrial chambers due to increased
circulatory blood volume, especially in freshwater drown-
ing. The postmortem pericardial BNP levels and BNP/ANP
ratio were markedly elevated in chronic congestive heart
disease cases, in which BNP levels correlated with the
grade of ventricular dilatation and heart and lung weights,
suggesting a relationship with gradually developing cardiac
hypertrophy, terminal pulmonary congestion, and oedema
as a consequence of fatal cardiac dysfunction.
Michaud et al. [60] investigated the postmortem stability
and levels of NT-proBNP in 96 forensic cases classified
into four groups according to autopsy and histological
findings (acute coronary ischemia, 18 cases; acute and
chronic coronary ischemia, 13 cases; chronic coronary
ischemia, 25 cases; and control group, 40 cases). NT-
proBNP levels in pericardial fluid, femoral blood, and
postmortem serum from femoral blood were similar,
suggesting that any of these fluids could be used for
postmortem testing, whereas NT-proBNP vitreous levels
were of no value. The highest NT-proBNP levels were
observed in individuals who had suffered from acute
coronary thromboembolism in association with chronic
cardiac ischemia.
Biochemical markers of myocardial ischemia
Biochemical markers of myocardial ischemia (cardiac
troponin I, cardiac troponin T, myosin, myoglobin, creatine
kinase, and creatine kinase MB) have been investigated by
several authors in postmortem serum from different
sampling sites and pericardial fluid, with sometimes
controversial results [61–67].
Osuna et al. [61] evaluated the diagnostic efficacy of
cardiac troponin I (cTnI) determination to diagnose acute
myocardial ischemia in pericardial fluid and postmortem
serum from femoral blood. This was carried out on 89
medico-legal autopsy cases, 25 of which were myocardial
infarction, classified into four groups according to autopsy
and histological findings. Their results suggested a high
diagnostic specificity for cTnI in pericardial fluid.
Ellingsen and Hetland [62] performed a study on 102
autopsy cases in order to assess the importance of
measuring cardiac troponin T (cTnT) in postmortem serum
from femoral blood and found that increased cTnT levels in
an otherwise negative autopsy could support a diagnosis of
sudden cardiac death.
Zhu et al. [64–66] analysed the cTnT, cTnI, and CK-MB
levels in pericardial fluid and postmortem serum from
different sampling sites in three series of medico-legal
autopsies. In an initial study performed on 405 medico-
legal autopsy cases, the authors observed that cTnT
measurements might be useful in investigating the severity
of myocardial damage due to various causes of death. In
general, cTnT levels in postmortem serum from heart blood
and pericardial fluid were higher than in postmortem serum
from peripheral blood, with an increase depending on
postmortem time, suggesting that the severity of myocardial
damage at the time of death contributed to the postmortem
leakage of cTnT from the myocardium. In a subsequent
study performed on 171 medico-legal autopsy cases (96
sudden cardiac deaths and 75 control cases), the authors
observed that increased cTnT levels in postmortem serum
from heart blood and pericardial fluid in sudden cardiac
deaths were correlated to the severity of ischemic myocar-
dial damage. In a third study performed on 234 medico-
legal autopsy cases, the authors observed that increased
cTnI levels in postmortem serum from heart blood and
pericardial fluid were linked to the morphological severity
of myocardial damage. On the contrary, CK-MB levels
seemed to be independent of the morphological severity of
myocardial damage.
Sepsis, inflammation, and infection
Procalcitonin
Serum procalcitonin (PCT), a protein of 116 amino acids
with a molecular weight of 13 kDa, is normally produced in
the C cells of the thyroid gland as the precursor to
calcitonin. A specific protease cleaves serum PCT to
calcitonin, catacalcin, and a N-terminal residue. Serum
PCT levels are therefore undetectable (<0.1 ng/ml) in
healthy humans. During severe bacterial infections with
systemic manifestations, however, serum PCT levels may
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increase to over 100 ng/ml. In these situations, serum PCT
is probably produced by extra-thyroid tissues. In fact,
patients who have previously undergone total thyroidecto-
my still produce high levels of serum PCT during severe
infection. The exact origin of serum PCT during sepsis is
uncertain and the pathophysiological role of PCT during
sepsis is not clear. Serum PCT levels increase during severe
generalised bacterial, parasitic, or fungal infections with
systemic manifestation. In severe viral infections, or
inflammatory reactions of non-infectious origin, serum
PCT levels do not increase or only show a moderate
increase. Compared with the relatively short half-lives of
cytokines such as tumour necrosis factor (TNF)-α and
interleukin-6 (IL-6), the half-life of serum PCT in the
systemic circulation is rather long, 25–30 h. Bearing in
mind these properties, PCT has been proposed as an
indicator of severe generalised infections or sepsis. Infec-
tions with no systemic manifestation cause a limited, if any,
increase in serum PCT levels. Systemic inflammatory
syndrome of non-infectious etiologies also leads to increases
in serum PCT levels though increased serum PCT levels may
be present without any evidence of severe infection in patients
subsequent to major trauma or surgery as well as post-
cardiopulmonary bypass. However, the median values under
these conditions are usually lower than those found during
severe sepsis and septic shock [68–74].
Tsokos et al. [75] investigated the use of PCT as a
postmortem marker of sepsis in 61 autopsy cases (eight
sepsis cases and 53 control cases). Postmortem serum was
obtained from femoral blood and postmortem PCT concen-
trations were compared with PCT concentrations measured
in antemortem serum samples. All sepsis cases showed
increased PCT levels, whereas PCT levels were undetect-
able in control cases. According to the authors, measurements
of PCT levels in sepsis-related fatalities seemed to be
reasonable up to at least approximately 140 h after death.
The authors also emphasized that, compared with other
biochemical markers (TNF-α, IL-6, and C-reactive protein),
PCTwas very stable even at room temperature and had a long
half-life (25 to 30 h). Moreover, repeated freezing and thawing
of the blood samples did not significantly influence its
concentration.
In a study performed by Ramsthaler et al. [76],
postmortem serum PCT levels were determined in 70
forensic and 78 clinical-pathological autopsy cases, in order
to evaluate whether a semi-quantitative test (rapid diagnos-
tic test) was a reliable indicator of PCT levels. Postmortem
serum was obtained from femoral vein blood. The results
showed that the introduction of a rapid diagnostic test could
be useful in achieving a rapid distinction between sepsis
and non-sepsis related causes of death, especially in
conjunction with the medical case history and further
autopsy results.
Acute-phase proteins and cytokines
The proinflammatory cytokine IL-6 is made up of a series
of phosphoglycoproteins with a molecular weight ranging
from 21 to 45 kDa. The serum reference limit of IL-6 is less
than 10 pg/ml in healthy individuals. It is a mediator of the
acute-phase response to inflammatory tissue injury. C-
reactive protein (CRP), the classical acute-phase protein,
is a non-glycosylated protein consisting of identical,
21 kDa non-covalently bound subunits. It is predominantly
produced and secreted by hepatocytes in response to the
release of inflammatory cytokines. The reference limit of
serum CRP concentrations in healthy individuals is less
than 10 mg/l [77].
IL-6 and CRP levels in peripheral blood or postmortem
serum from femoral blood have been investigated by
several authors. The results have showed that both markers,
particularly CRP, can be used in forensic routine similar to
clinical practice [78–82].
Astrup and Thomsen [80] investigated CRP levels in 50
forensic autopsy cases in different samples, including liver.
They found that liver CRP levels correlate well with
postmortem serum levels, suggesting the possibility of
using liver samples as an alternative to postmortem serum
for CRP determination.
Maeda et al. [81] analysed urea nitrogen, creatinine, and
CRP postmortem serum levels in 429 medico-legal autopsy
cases and found that the combined use of these three
markers could be useful for postmortem investigations of
death due to hyperthermia, especially in the absence of
pathological and toxicological evidence.
Reichelt et al. [83] investigated interleukin-1β (IL-1β),
soluble interleukin-2 receptor (sIL-2R) and lipopolisacchar-
ide binding protein (LBP) in postmortem serum from
femoral blood in two series of autopsy cases (eight septic
cases and 16 control cases). IL-1β is predominantly
produced by monocytes/macrophages as an inactive
31 kDa precursor protein (pIL-1β) and is processed to its
active 17.5 kDa form by the specific interleukin-1β
converting enzyme. The reference limit of IL-1β serum
concentrations in living individuals is less than 5 pg/ml.
sIL-2R is a marker of lymphocyte activation, with a
molecular weight between 40 and 45 kDa and is produced
by T cells and granulocytes. The reference value of sIL-2R
in healthy individuals is below 1,000 U/ml. The acute-
phase protein LBP is a 60-kDa serum glycosylated protein,
forming high-affinity complexes with bacterial endotoxins
(lipopolysaccharide), functioning as an opsonin, that is
produced and secreted by hepatocytes. The reference limit
of LBP in healthy individuals is less than 10 μg/ml [83–
85]. The results of this study showed increased sIL-2R and
LBP postmortem serum levels over the clinical reference
limits in sepsis-related fatalities, suggesting that these
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markers could be an appropriate diagnostic tool, in
combination with other biochemical markers, in the
postmortem diagnosis of sepsis in forensic autopsy practice.
Schrag et al. [86] investigated CRP, PCT, TNF-α, IL-6,
and IL-8 levels in postmortem serum from femoral blood in
two series of autopsy cases (eight septic cases and ten
control cases), in order to evaluate their applicability as
postmortem markers of sepsis. They also compared CRP
and PCT values in postmortem serum, vitreous, and
cerebrospinal fluid in a series of sepsis-related fatalities
and control subjects. The results showed that PCT was
more reliable than the other mentioned parameters in the
postmortem diagnosis of sepsis, thus allowing a better
differentiation between sepsis-related fatalities and non-
sepsis-related fatalities. Moreover, PCT penetrated the
blood–vitreous barrier, with detectable values in cases of
sepsis. Detectable CRP values could also be found in
vitreous and cerebrospinal fluid in cases of sepsis with
increased CRP and PCT levels.
Multiple organ failure of various non-infectious causes
(including trauma, burn, myocardial infarction, and pancrea-
titis) are well known to induce a rise in inflammatory cytokine
levels. Mimasaka et al. [87–90] performed several studies on
postmortem cytokine levels (including granulocyte-
macrophage colony-stimulating factor (GM-CSF), interferon
(IFN)-γ, TNF-α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10,
and IL-13) in postmortem serum from cardiac blood and
concluded that IL-6 and IL-8 could differentiate traumatic
and non-traumatic deaths, supporting the diagnosis of
traumatic death in the former.
Neopterin
Neopterin is a biochemical product of the guanosine
triphosphate pathway produced primarily in monocyte/
macrophage and related cells, upon stimulation of interfer-
ons, especially Th1-type cytokine IFN-γ. High neopterin
concentrations in serum and urine have been shown to be a
reliable indicator of the severity of viral, bacterial, proto-
zoic, parasitic, or fungi-induced infections including the
ensuing systemic inflammatory response syndrome. Corre-
lations between neopterin levels and disease state have also
been reported for rheumatoid arthritis, insulin dependent
diabetes mellitus, systemic lupus erythematosus, multiple
sclerosis, celiac disease and rheumatic fever. In various
types of malignant diseases, increased neopterin concen-
trations can be predictive in tumour progression, metastasis
development, and mortality. Although not produced by
tumour cells themselves, increased neopterin concentrations
most likely reflect the host defense reaction elicited by the
aggressiveness of the tumour. Furthermore, augmenting
concentrations of neopterin have been found to be a valid
indicator of graft rejection and/or infectious complications
following kidney, heart, liver, lung, pancreas, and bone
marrow transplants [91, 92].
Forensic use of neopterin has been investigated by
Ishikawa et al. [82] and Ambach et al. [93, 94] in
postmortem serum from various sampling sites and urine.
Autopsy cases with diagnoses indicating cellular immuno-
logical background showed increased urine and postmortem
serum levels comparing to control cases. Postmortem serum
neopterin levels over 500 nmol/l were observed in cases of
delayed death due to trauma involving the systemic
inflammatory response syndrome as well as fatal bacterial
and viral infections.
Anaphylaxis
Tryptase and chymase
Mast cells are heavily granulated, wandering cells found in
connective tissues and in abundance beneath epithelial
surfaces. They circulate in blood as precursors and are
recruited into peripheral tissues such as the dermis of the
skin and lungs as well as the mucosa and submucosa of the
intestine, where they differentiate and mature. Mast cell
granules contain heparin, histamine, and many proteases
such as tryptase and chymase. The extracellular release of
mediators, known as degranulation, may be induced by
immune mechanisms (IgE dependent and IgE independent)
as well as other factors. IgE receptors are present on the
mast cell membranes. When IgE-coated antigens bind to
surface receptors, mast cell degranulation occurs. Anaphy-
laxis is defined as a condition caused by an IgE-mediated
reaction, whereas anaphylactoid reactions are defined as
those reactions that produce the same clinical picture as
anaphylaxis but are not IgE mediated. Mast cell tryptase is
a tetrameric neutral serine protease with a molecular weight
of 134 kDa and made up of four non-covalently bound
subunits, each one with an active site. There are two main
types of mast cell tryptase, α-tryptase and β-tryptase.
β-Tryptases are classified into βI-, βII- and βIII-tryptases
and the α-tryptases into αI- and αII-tryptases. βII-Tryptase is
stored in the secretory granules of mast cells. In contrast,
α-tryptase is not stored and is secreted constitutively from
mast cells as an active proenzyme. Hence, it is the major form
of tryptase found in the blood of normal subjects and does not
contribute to the increase in tryptase levels following acute
mast cell degranulation [95–98].
Analyses of total immunoglobulin E and specific IgE are
possible in postmortem serum though only atopic disposi-
tion and the individual’s degree of sensitisation can be
verified, hence not proving that death was preceded by
acute anaphylactic reaction. Histamine degrades too rapidly
after death to be a reliable postmortem marker. Tryptase is
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more stable, has a longer half-life and can be detected from
a few minutes up to several hours after mast cell
degranulation [99, 100]. Analyses of tryptase in postmor-
tem serum samples of suspected anaphylaxis and anaphy-
lactoid reactions have consistently shown elevated values
[99–112]. However, increased tryptase levels have also
been demonstrated in other situations, including sudden
death infant syndrome, acute death after heroin injection,
atherosclerotic cardiovascular disease, and traumatic death
[100, 111, 113–122].
Some studies have indicated that tryptase may have a
correlation with increased postmortem intervals, with
concentrations varying on sampling site. Edston and van
Hage-Hamsten [100] found that tryptase levels were
generally higher in postmortem serum than in the serum
from living patients, possibly due to postmortem passive
diffusion. A weak positive correlation between heart blood
and pericardial fluid also suggested the possibility of
postmortem diffusion between these compartments. In a
study performed in 2007 on 60 cases, including five
anaphylactic deaths, Edston et al. [111] measured tryptase
in postmortem serum from femoral and heart blood and
proposed a value of 45 μg/l in postmortem serum from
femoral vein blood as a reference limit in order to eliminate
the possibility of false positives.
Da Broi and Moreschi [123] reviewed the literature
concerning the postmortem diagnosis of anaphylaxis and
emphasized that, because of the artificial increases of
biochemical markers induced by the onset of postmortem
cytolytic processes, postmortem serum from blood samples
immediately obtained during resuscitation procedures as
well as urine samples obtained immediately before or after
death should be used to measure tryptase (in serum) and
N-methylhistamine (in urine).
Mayer et al. [124] measured tryptase, histamine, and
diamine oxidase in postmortem serum from femoral blood
in 58 forensic cases including three anaphylactic deaths.
They concluded that while moderately elevated tryptase
levels were also common in control cases, values above
45 μg/l, as suggested by Edston et al., would support the
diagnosis of fatal anaphylaxis. Strongly elevated histamine
levels could further corroborate this hypothesis, whereas
diamine oxidase did not prove helpful in confirming the
diagnosis.
The forensic use of chymase, a mast cell-derived serine
protease, was investigated by Nishio et al. [125], who tested
the usefulness of this marker in the postmortem diagnosis
of anaphylaxis. Postmortem serum from heart blood was
analysed in 112 cases, including eight anaphylactic deaths.
Chymase was detected in all anaphylactic cases but only in
two control cases (myocardial infarction in both cases). The
authors also examined the relationship between chymase
and tryptase levels in all eight chymase-positive cases and
found a significant positive correlation between the two
markers, suggesting that measurement of serum mast cell-
specific chymase levels could be an additional method for
postmortem diagnosis of anaphylaxis.
In our medico-legal centre, we observed a case of fatal
anaphylactoid reaction following the injection of 10 ml of a
gadolinium-based contrast agent in a 63-year-old man.
Some minutes after the injection, he developed a general-
ised itch, became flushed, started coughing, and showed
signs of respiratory difficulties before losing consciousness.
All attempts at reanimation proven unsuccessful and the
patient died after 1 h. Postmortem serum was immediately
obtained from femoral blood. Tryptase level was 181 μg/l.
Vitreous tryptase was undetectable. Gadolinium concentra-
tions in femoral blood and postmortem serum from femoral
blood were similar and consistent with the administration of
10 ml of a gadolinium-based contrast agent.
Hormones
Adrenocorticotropic hormone
Ishikawa et al. [126] investigated adrenocorticotropic
hormone (ACTH) levels in postmortem serum from cardiac
blood and cerebrospinal fluid in 162 forensic autopsy cases.
They also compared the results with immunohistochemical
investigations in the anterior pituitary gland. Postmortem
serum levels varied depending on the cause of death.
Cerebrospinal fluid levels were usually higher than post-
mortem serum levels, but significantly lower in cases of
hypothermia. A decrease in the ACTH-immunopositivity
rate in the anterior pituitary gland was also revealed in these
cases, dependent on the postmortem serum levels. In
accordance with the results of a previous study [127], the
authors postulated that in a cold environment, ACTH
production could initially increase to generate heat to then
be suppressed due to metabolic disorders involving abnor-
mal lipid metabolism in advanced hypothermia. They
concluded that low ACTH levels in cerebrospinal fluid
could suggest an exhausted pituitary function due to
prolonged exposure to cold.
Thyroid stimulating hormone, thyreoglobulin, and thyroid
hormones
Several studies have been performed in order to detect
increased thyreoglobulin (Tg), thyroxine (T4), and triiodo-
thyronine (T3) levels in postmortem serum or blood in
subject who died by hanging, ligature, or manual strangu-
lation [128, 129]. Müller et al. [128] observed the highest
Tg concentrations in the postmortem serum from heart
blood in cases of incomplete suspension and manual
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strangulation. Similarly, Şenol et al. [129] found increased
heart blood Tg and T3 levels and normal heart blood
thyroid stimulating hormone (TSH), T4, calcitonin, para-
thormone, and amylase levels in hangings.
Edston et al. [130] investigated TSH, T3, and T4 levels
in femoral blood and vitreous humor in 38 forensic autopsy
cases and found that T3 and T4 did not cross the vitreous–
blood barrier, whereas blood levels were fairly comparable
to antemortem clinical reference values.
Dressler and Müller [131] studied Tg levels in cases of
fatal traumatic brain injuries in serum from mixed blood
from both cardiac ventricles. They also compared the
results with immunohistochemical investigations in the
anterior pituitary gland and thyroid. The results showed
increased Tg serum levels, closely linked to a low TSH
activity in the hypophysis and Tg reactions in the thyroid,
suggesting that damages to the hypothalamus and hypophysis
through trauma caused acute and excessive hormonal release
(TSH and Tg) as well as disturbances in the feedback
mechanism.
Ishikawa et al. [132] investigated TSH levels in postmor-
tem serum from cardiac blood and cerebrospinal fluid in 120
forensic autopsy cases. They also compared the results with
immunohistochemical investigations in the anterior pituitary
gland. Postmortem serum levels varied depending on the
cause of death but were significantly lower in hypothermia
cases, which also showed lower TSH levels in cerebrospinal
fluid and a low TSH-immunopositivity rate in the anterior
pituitary gland. The authors postulated that in a cold
environment, TSH production, as with ACTH production,
could initially increase to generate heat only to be subse-
quently suppressed by metabolic disorders involving abnor-
mal lipid metabolism in advanced hypothermia. They
concluded that low TSH levels in cerebrospinal fluid could
suggest exhausted pituitary function due to prolonged cold
exposure.
Catecholamines
Postmortem serum catecholamine levels in relation to the
cause of death have been investigated by Zhu et al. [133]
and Wilke et al. [134]. Zhu et al. [133] analysed
catecholamine levels in 542 autopsy cases in postmortem
serum from different sampling sites and found that
increases in catecholamine fractions (adrenaline, noradren-
aline, and dopamine) depended on the cause of death as
well as the magnitude of physical stress responses during
the death process in individual cases. Wilke et al. [134]
analysed catecholamine levels in femoral blood, heart
blood, cerebrospinal fluid, urine, and vitreous in 98 autopsy
cases divided into four groups (short agony, long agony,
hanging asphyxiation, and cardiopulmonary resuscitation).
Absolute values for adrenaline and noradrenaline in heart
and femoral blood displayed no significant differences in
relation to the cause of death and length of agony. In a
similar manner, recorded catecholamine values in cerebrospi-
nal fluid and urine did not allow any conclusions pertaining to
the cause of death or the length of agony to be made. On the
contrary, vitreous values warranted significant conclusions at
least in cases that underwent cardiopulmonary resuscitation,
and could be clearly distinguished from cases with short and
long agony. Ishikawa et al. [135] investigated catecholamine
levels in postmortem serum from cardiac blood and
cerebrospinal fluid in 290 forensic autopsy cases. They also
compared the results with immunohistochemical investiga-
tions in the hypothalamus, adenohypophysis, and adrenal
medulla. Postmortem serum and cerebrospinal fluid levels
were reduced in hypothermia cases. Moreover, a positive
correlation between cerebrospinal fluid noradrenaline levels
and noradrenaline immunopositivity in the adrenal medulla
in hypothermia cases suggested a systemic, progressive
deterioration of the sympathetic/adrenomedullary system
due to fatal cold exposure.
Cortisol
No extensive investigations have been performed on
cortisol levels in postmortem serum and urine, with the
exception of the study carried out by Finlayson [136] on 35
autopsy cases (15 infants and children and 20 adults).
Similar values in postmortem serum from femoral and right
atrial blood, averaging 18 μg/dl (497 nmol/l, not unlike
normal values obtained during life), were found in both
study groups. Finlayson emphasized that a small decrease in
cortisol levels was also found during the first 18 h after death.
Some cases of adrenocortical insufficiency have been
mentioned in literature where the postmortem diagnosis was
usually obtained by combining immunohistochemical inves-
tigations in the adrenal cortex with the measurement of
cortisol in peripheral blood or in postmortem serum from
peripheral blood and the measurement of cortisol and
17-hydroxycorticosteroid in urine [137–140].
Chorionic gonadotropin
Fanton et al. [141] investigated human chorionic gonadotro-
pin (HCG) in postmortem serum (from peripheral or cardiac
blood), vitreous, and bile in 39 forensic autopsy cases (five
pregnant women and 34 presumed non-pregnant women) and
observed HCG-positive results in all substrates from pregnant
women and no HCG-positive results in the control cases.
Erythropoietin
Erythropoietin (EPO) is a glycoprotein hormone made up
of 165 amino acids with a molecular weight of 30–35 kDa
206 Int J Legal Med (2012) 126:199–215
that regulates erythropoiesis by binding to a receptor on the
surface of erythroid progenitor cells. The primary sites for
EPO synthesis is the peritubular fibroblasts of renal cortex
cells in adult humans and hepatocytes in foetuses. The main
stimulus for increased EPO production is tissue hypoxia.
EPO levels increase as early as 2 h post-anaemia and/or
systemic hypoxia initiation with a half-life of about 5–9 h.
Most anaemic patients have an elevated plasma EPO
concentration that depends on the degree and type of
anaemia. However, plasma EPO in patients with anaemia
from chronic renal failure is usually inappropriately low
due to reduced EPO synthesis by the kidney [142, 143].
Quan et al. [143] investigated EPO levels in postmortem
serum from various sample sites (left and right heart and
external iliac vein) in 536 forensic autopsy cases. No
difference was observed depending on the sampling site,
and values were within the clinical reference range in most
cases. A survival time-dependent increase was mainly seen
in protracted deaths due to blunt injury and fire fatality,
suggesting the systemic influence of anaemia/hypoxia
following massive bleeding and/or tissue damage. Similar
findings in subacute deaths from gastrointestinal bleeding
and infectious diseases were related to the severity and
duration of bleeding/anaemia or advanced hypoxia in the
death process. In a subsequent study, the authors [144]
investigated EPO levels in postmortem serum from differ-
ent sampling sites in 185 injury death cases (sharp
instrument injury and blunt injury) and compared them
with CRP levels. Survival time-dependent increases in EPO
levels within about 6 h were observed in cases of sharp
instrument injury to the heart or a proximal major vessel as
well as blunt injuries with massive haemorrhages. These
findings suggested that bleeding velocity was the main
factor in early EPO level elevation, possibly due to the
rapid progression of renal ischemia and hypoxia. In
contrast, serum CRP levels gradually increased about 12–
24 h after a blunt injury, suggesting that postmortem serum
EPO could be a marker for investigating survival time
within 6 h of major injury involving acute, massive
haemorrhage.
Miscellaneous
Chromogranin A
Chromogranin A (CgA) is a 49–68-kDa calcium-binding
glycoprotein, originally isolated as a major soluble protein
in adrenal medullary chromaffin granules. It is widely
distributed in the secretory granules of endocrine and
neuroendocrine cells and cosecreted with hormones such
as catecholamine. Yoshida et al. [145] investigated CgA
and catecholamine levels in postmortem serum from cardiac
blood and cerebrospinal fluid in 298 forensic autopsy cases
and compared the results with immunohistochemical inves-
tigations in the hypothalamus, adenohypophysis, and adrenal
medulla. Postmortem serum CgA levels were generally higher
than clinical reference values. Hypothermia cases tended to
show lower CgA levels in postmortem serum and increased
levels in cerebrospinal fluid. Low hypothalamus neuronal
CgA immunopositivity with a positive correlation to CSF
CgA levels was also found, suggesting a terminal state of
hypothalamus dysfunction involving the depletion of CgA-
containing secretory granules in prolonged death due to cold
exposure.
S100B
The S-100 protein is a 10–12-kDa calcium-binding protein.
Its subunit B (S100B) is highly specific for astrocytes,
oligodendrocytes, and ependymocytes in the central ner-
vous system. S-100B is clinically used as a serum marker
of brain damage due to cerebral injury and hypoxia/
ischemia in the evaluation of neurological prognosis. Li et
al. performed several studies [146–149] to evaluate S100B
levels in postmortem serum and cerebrospinal fluid, as well
as the immunohistochemical distribution of S-100 protein
in the cerebral cortex, with regard to the cause of death. In
an initial study performed on 283 medico-legal autopsy
cases, the authors measured S100B levels in postmortem
serum from various sample sites and found increased
S100B levels in postmortem serum from right heart blood
and subclavian vein in cases of acute deaths from head
injury and asphyxiation due to neck compression. In a
subsequent study performed on 286 medico-legal autopsy
cases, the authors observed an inverse relationship between
S100 positivity in the astrocytes and serum S100B levels in
cases of acute deaths, suggesting that astrocytes were more
rapidly and severely injured than neurons during fatal brain
damage. In a third study performed on 216 medico-legal
autopsy cases, the authors measured S100B levels in
postmortem serum from heart blood and cerebrospinal fluid
and concluded that CSF S100B levels could be used in
assessing brain damage severity due to injury and cerebral
hypoxia/ischemia as a consequence of fatal trauma.
Serotonin
Quan et al. [150] investigated serotonin (5-HT) levels in
cerebrospinal and pericardial fluids with regard to the cause
of death in 351 medico-legal autopsy cases. The postmor-
tem 5-HT concentration in cerebrospinal fluid was similar
to that described in a previous study carried out by
Musshoff et al. [151] and higher than the clinical reference
value, whereas the postmortem 5-HT level in pericardial
fluid overlapped with the clinical serum level. Particularly
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higher serotonin values in both fluids were observed in
cases of sedative-hypnotic drug intoxication as well as of
hyperthermia cases, whereas hypothermia cases tended to
show low 5-HT levels. According to the authors, the results of
the study would indicate that a systemic neuronal dysfunction
might be involved in these causes of death, as already
suggested by previous investigations which indicated in the
same situations similar changes in catecholamine levels
observed in postmortem serum from cardiac blood and
cerebrospinal fluid [133–135].
Myoglobin
Myoglobin levels in postmortem serum from femoral and
cardiac blood with special references to electrical fatalities
have been investigated by Püschel et al. [152] and Fieguth
et al. [153]. Zhu et al. [154] evaluated urinary myoglobin
levels in 210 forensic autopsy cases, partially in comparison
with concentrations observed in postmortem serum from
cardiac blood (72 cases). Myoglobin levels in urine did not
correlate with serum levels. Postmortem changes including
bladder wall muscle autolysis, tissue damage at time of death
and prolonged survival time were identified as factors capable
of inducing postmortem urinary myoglobin elevations. In-
creased myoglobin levels in urine were observed in heat
stroke cases, fatal burns, and situations with massive skeletal
muscle damages, muscle hyperactivity or convulsive disor-
ders associated with hypoxia immediately before death.
Conclusions
In this article, a review of the literature concerning several
biochemical markers which can be implicated in many
current forensic situations (liver insufficiency, alcohol
misuse and intake, myocardial ischemia, inflammation,
infection, sepsis, anaphylaxis, hormonal diseases, anaemia
or hypoxia, and brain damage) has been presented (Table 1).
The contribution that these markers can provide in investi-
gating the cause of death is not negligible. For instance,
increased postmortem serum PCT levels, combined with
cytokines and acute-phase proteins serum raises, histological
and immunohistochemical findings consistent with infection
and positive microbiology investigation results, can corrob-
orate the hypothesis of death following sepsis. At the same
time, the observation of increased PCT levels, without
any other macroscopical and microscopical finding, can
represent a source of confusion and be of no value in
understanding the mechanisms leading to death. The
same observation can be extended to other biochemical
markers, e.g. tryptase and cardiac troponins. Of course,
increased CDT levels can easily be interpreted as the
biochemical sign of alcohol misuse and severe perturbationsTa
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in total cholesterol, bilirubin, and total protein levels in
postmortem serum obviously represent the result of liver
disease. The presence of macroscopical and microscopical
finding consistent with liver cirrhosis and the perturbation of
the biochemical parameters linked to the liver function
corroborate the hypothesis of liver insufficiency as cause of
death. However, it could be pretentious to conclude that the
cause of death is “liver insufficiency” only on the basis of
increased postmortem serum levels of these markers and
without any other radiological or morphological findings.
Maximum prudence is also required in interpreting increased
postmortem levels of cardiac markers to avoid yielding to the
temptation of establishing direct links between postmortem
cardiac troponin levels and sudden deaths. Once again, we
strongly suggest an “intelligent” approach to postmortem
chemistry, consisting of incorporating these analyses among
the routine forensic and medico-legal investigations, with the
same importance as radiology, histology, and toxicology, but
above all in interpreting the results in a larger clinical and
forensic context. The aim of postmortem chemistry must not
be “limited” to determining the cause of death, but extended to
understanding the pathophysiological mechanisms involved
in death process.
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